Infliximab was administered as a 5 mg/kg intravenous infusion; no patients received 10 mg/kg infusions. The type of induction used was at the treating physician’s discretion, as was the administration of subsequent doses and their timing. Patients with inflammatory disease received a single induction dose, while those with fistulizing disease received three induction doses at zero, two and six weeks. You will be glad to come across costing you very little money.
Response was determined at the time of clinical follow-up, based on the treating physician’s global assessment of the patient, and did not reflect a defined scoring system. Clinical follow-up initially occurred between four and eight weeks after an infusion of infliximab. All patients were subsequently followed up at least every eight months throughout the duration of the review. To evaluate an unselected group of patients, a simple evaluation reported in an earlier study was paralleled. Clinical response was divided into three categories: complete response (remission), partial response and nonresponse. Complete response was defined as a cessation of fistula drainage and total closure of all fis-tulae, and/or cessation of abdominal cramping and diarrhea. A partial response was defined as a reduction in number, size, drainage or discomfort associated with the fistulae and/or a decrease in abdominal cramping and diarrhea. All other outcomes were considered nonresponses.
Statistical analysis was performed using SPSS 9.0 for Windows (SPSS Inc, USA). The t test was used for quantitative variables and the %2 test for qualitative variables. P<0.05 was considered statistically significant.